Company profile

Who We Are


InnovHeart s.r.l., with locations in Milan, Italy, and Boston, Massachusetts, develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. The company is preparing for clinical trials of its novel TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve. Saturn is a low-profile prosthetic designed for both Trans-apical and Trans-septal delivery. InnovHeart is backed by leading investor Genextra S.p.A, an Italian-based holding company specializing in early-stage investments in the life sciences sector.


Our company mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology. ​InnovHeart is committed to pursuing this goal with the highest level of quality.

Board of Directors

DAWKINS Keith D. – Chairman of the Board
Keith has more than 35 years of experience as both a practicing physician and an executive within the medical device industry. From 2012 to 2017 Keith served as Executive Vice President and Global Chief Medical Officer at Boston Scientific. His responsibilities included overseeing the clinical function for all six Divisions, as well as leading Medical Affairs in Europe and Latin America, Health Economics in Europe, and Pre-Clinical Sciences for the company. Before that, Keith served as Senior Vice President and CMO for the Boston Scientific Cardiology Rhythm and Vascular Group.
Prior to joining Boston Scientific, Keith was a practicing interventional cardiologist for over 20 years in the U.K. He was President of the British Cardiovascular Intervention Society (2000 – 2004), and member of the Interventional Procedure Advisory Committee (IPAC) with the National Institute for Health and Clinical Excellence (NICE) for a period of four years. Keith earned a First-Class Honours degree in Pathology at London University and Guy’s Hospital. He trained in cardiology at Oxford and at the Royal Brompton and St. George’s Hospital in London.

Jason has more than 22 years of experience in the medical device industry, including 18 in the interventional cardiovascular market. Before joining InnovHeart, Jason was Chief Executive Officer of Infraredx, a start-up company developing a novel intravascular imaging system for the detection of lipid core plaque in coronary artery disease. Under Jason’s leadership, Infraredx was acquired by Nipro Corporation, confirming him as CEO of the Company. Prior to Infraredx, Jason was one of the founding US sales leaders in the Italy-based Invatec, a Company acquired by Medtronic to become the foundation of its peripheral vascular business unit. Jason’s management experience also includes leadership positions at Spectranetics Corp. and Cordis, a Johnson & Johnson Company, where he directed global training and was part of a core team assembled to launch the world’s first drug eluting stent (Cypher).

RIGHINI Giovanni – Founder
Giovanni has over 30 years of experience in bringing innovative implantable cardiac devices from feasibility to market, as well as an extensive track record in successful R&D project execution. Giovanni has more than 30 patent applications in Transcatheter Heart Valve replacement. Giovanni was formerly founder of HT-Consultant, VP R&D at Symetis SA, R&D Director at Sorin Group. He holds a M.S. in Electrical Engineering from University of Pisa, Italy.

DRAGHI Federica
Federica is the Director of Business Development at Genextra, which she joined in 2006. Before joining Genextra, Federica was at Windham Venture Partners, NYC, and prior to that was with Science and Technology Ventures, Columbia University’s tech transfer office. Previously, she was a postdoc at the MRC in Cambridge (UK) and was published in several journals. Federica holds an MBA from Columbia University and a PhD in Biochemistry from La Sapienza, University of Rome

Paolo has been Genextra’s chief financial officer since its inception in 2004 and he has served as a member of the board of directors of Genextra’s portfolio companies. In particular, he is currently Chairman of Intercept Pharmaceutical, Director of Erydel, Managing Director of Congenia. In addition, Paolo is also a founder and a Board Member of the Italian Angels for Biotech. Before joining Genextra, Paolo was in charge of finance and strategic planning for Fastweb from 2000 to 2004. Previously, he worked in London for investment banks, including Salomon Smith Barney (now Citigroup) and Donaldson Lufkin & Jenrette (now Credit Suisse). Paolo has a degree in Business Management from Bocconi University in Milan, Italy.

RATZ Brent
Brent is a successful medical device entrepreneur with over 19 years of experience in the industry. He is the co-founder and Managing Director of inQB8 Medical Technologies, a holding company creating novel technologies and companies to address major unmet clinical challenges in cardiovascular health. He was the founding CEO, President and COO of CardiAQ Valve Technologies, a Transcatheter Mitral Valve Replacement (TMVR) company, which he co-founded in 2006 and led for the next 9 years through development and initial clinical feasibility until it was acquired by Edwards Lifesciences in 2015 for $350M upfront, plus milestones. Following the acquisition, Brent remained with EW for 2 years as VP R&D TMVR supporting the integration, the US Early Feasibility trial, and next generation development. Since leaving EW in 2017, Brent has served as an independent consultant for numerous early-stage device companies and has supported due diligence efforts for several investment funds. Prior to starting CardiAQ, he spent 7 years with UTI/Accellent (now Integer), a leading provider of contract design, development and manufacturing services for the medical device industry, where he was responsible for the Project Management Group in their Corporate Development Center. Brent is a named inventor on more than 24 medical device patents and serves as a member of the Board of Directors for Access Vascular, Inc. He earned his BSE in Biomedical Engineering from Duke University and a Masters in Business Administration from The Wharton School, University of Pennsylvania.

SCARINCI Daniele Timothy
Daniele has been in charge of Business Planning and Controlling at Genextra since he joined in 2006. Before that, he worked at Italian TLC operator Fastweb in the strategic planning and investor relations departments. Previously, he worked in London as an equity analyst. Daniele has a degree in Economics from Tor Vergata University in Rome, Italy.


Cookies help us to give you tailored experiences on our website. By accessing in our site, you expressly agree that we may use cookies on your devices.If you do not wish to accept the use of cookies, you can adapt the settings in your web browser. Read more

Cookies help us to give you tailored experiences on our website. By accessing in our site, you expressly agree that we may use cookies on your devices.If you do not wish to accept the use of cookies, you can adapt the settings in your web browser.